FDA Approves Acalabrutinib with Venetoclax for CLL or SLL By Ogkologos - March 4, 2026 241 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR Ovarian Reserve Better Indicator of Adjuvant Chemotherapy Benefit than Self-Reported Menopause Status, Age, or Other Hormone Levels Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into More Inflamed Tumours and Improve Response EMA Recommends Extension of Therapeutic Indications for Serplulimab MOST POPULAR FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... April 15, 2022 Commemorating the Contributions of Cancer Research Greats March 12, 2021 A celebration of peer review September 21, 2021 FDA Grants Accelerated Approval to Sonrotoclax for Relapsed or Refractory Mantle... May 27, 2026 Load more HOT NEWS The rise of the ‘long-waiter’ – why cancer waiting times are... EMA Recommends Granting a Marketing Authorisation for Toripalimab ‘Jeopardy!’ Legend James Holzhauer Donates Portion Of Winnings To Cancer Walk... Female Representation at the Top of the Oncology Field Has Hit...
